Plandai Biotechnology Inc (OTCMKTS:PLPL) the maker of the bio-available constituent identified as Phytofare® catechin complex revealed that Ultimate Sports Nutrition will be developing unique product line that contains Phytofare. These new products are meant to be sold in the New Zealand and Australian markets. In the past, the wellness and nutrition firm has used Phytofare® in the products commercialized in Europe as well as South Africa. This change comes as the two companies expand their agreement.
After making a high of $0.140 earlier in September, the share price of Plandai is declining on the charts. However, on Wednesday’s trading session, the stock halted its decline and gained more than 6% to close the trading session at $0.139.
Eastgate Biotech Corp (OTCMKTS:ETBI) Submits Form 10-Q
Eastgate Biotech Corp (OTCMKTS:ETBI) filed Form 10-Q wherein it revealed that the company generated revenue for the first time since inception. It was a result of robust sales in natural products vertical. For the quarter ending June 30, 2015, the company reported a net loss of $827,209 versus a net loss of $1.89 million in the comparable period, a year earlier.
The sharp decline in net loss can be attributed to the reduced G&A expenses that came at $1.06 million. Eastgate disclosed that the R&D expenses increased by $30,064 while and selling and marketing expenses jumped by $20,707. The professional fees dropped by $6,309 and this decline in expenses together with higher gross profit on sales prompted lower loss in the quarter.
Novadel Pharma Inc (OTCMKTS:NVDL) last issued its PR in January 2015 wherein it disclosed that it sold its assets, comprising of the NDA for ZolpiMist®, a license deal and related international intellectual asset to Amherst Pharmaceuticals, LLC, in lieu for presumably $2.2 million in payment owed to the U.S. FDA linked to ZolpiMist. They need to pay the amount by end of 2015.
